Neurovalens launched its first product, Modius Sleep, for the treatment of chronic insomnia in the U.S. Belfast, Northern Ireland-based Neurovalens designed Modius Sleep to deliver non-invasive electrical stimulation. It stimulates key areas of the brain and nervous system without the need for surgically implanted electrodes.
Related: CytexOrtho gets FDA approval for first-in-human trial of absorbable hip implants
The device uses electrical vestibular nerve stimulation (VeNS), delivering electrical pulses to the vestibular nerve. This influences the areas of the hypothalamus and brainstem that control circadian rhythm and sleep patterns.
Modius delivers a small, safe electrical pulse to the head for a period of 30 minutes before bed. During this period, users can perform other activities, like watching television or reading. Clearance allows Neurovalens to sell Modius directly to people suffering from chronic insomnia in the U.S. with a prescription.
The company won FDA clearance for the Modius Sleep device about a year ago. It picked up clearance for its Modius Stress device earlier this year, too.
According to a news release, published data on Modius Sleep demonstrated improved sleep for 95% of trial participants after four weeks.
“Sleep is critically important to our overall health,” said Dr. Jason McKeown, CEO of Neurovalens, “and I was deeply concerned by the amount of sleeping pills and sedatives my patients were relying on to get it. The truth is these medications weren’t working, and I knew there was a better way to treat chronic insomnia and other sleep disorders through my research and training in neurotechnology.
“It was important to us to develop a non-surgical option for patients with chronic insomnia. By non-invasively tapping into the brain’s natural sleep cycles, Modius Sleep allows you to fall asleep faster and stay asleep longer.”
